Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

被引：15
|
作者：
Chevallier, Patrice [1 ]
Robillard, Nelly [1 ]
Ayari, Sameh [1 ]
Guillaume, Thierry [1 ]
Delaunay, Jacques [1 ]
Mechinaud, Francoise [1 ]
Avet-Loiseau, Herve [1 ]
Mohty, Mohamad [1 ]
Harousseau, Jean-Luc [1 ]
Garand, Richard [1 ]
机构：
[1] Ctr Hosp Univ, Dept Haematol, Nantes, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 143卷 / 05期
关键词：
acute myeloid leukaemia; Gemtuzumab; Mylotarg; CD33; phenotype;
D O I：
10.1111/j.1365-2141.2008.07153.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：744 / 746
页数：3
相关论文
共 50 条
  • [1] Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
    Khan, N.
    Hills, R. K.
    Virgo, P.
    Couzens, S.
    Clark, N.
    Gilkes, A.
    Richardson, P.
    Knapper, S.
    Grimwade, D.
    Russell, N. H.
    Burnett, A. K.
    Freeman, S. D.
    LEUKEMIA, 2017, 31 (05) : 1059 - 1068
  • [2] Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
    N Khan
    R K Hills
    P Virgo
    S Couzens
    N Clark
    A Gilkes
    P Richardson
    S Knapper
    D Grimwade
    N H Russell
    A K Burnett
    S D Freeman
    Leukemia, 2017, 31 : 1059 - 1068
  • [3] Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
    Arceci, RJ
    Sande, J
    Lange, B
    Shannon, K
    Franklin, J
    Hutchinson, R
    Vik, TA
    Flowers, D
    Aplenc, R
    Berger, MS
    Sherman, ML
    Smith, FO
    Bernstein, I
    Sievers, EL
    BLOOD, 2005, 106 (04) : 1183 - 1188
  • [4] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse
    Sievers, EL
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (05) : 893 - 901
  • [5] The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
    Olombel, Guillaume
    Guerin, Estelle
    Guy, Julien
    Perrot, Jean-Yves
    Dumezy, Florent
    de labarthe, Adrienne
    Bastie, Jean-Noel
    Legrand, Ollivier
    Raffoux, Emmanuel
    Plesa, Adriana
    Wagner-Ballon, Orianne
    Cornet, Edouard
    Salaun, Veronique
    Preudhomme, Claude
    Thomas, Xavier
    Pautas, Cecile
    Chantepie, Sylvain
    Turlure, Pascal
    Castaigne, Sylvie
    Dombret, Herve
    Feuillard, Jean
    BLOOD, 2016, 127 (17) : 2157 - +
  • [6] CD33 antibody-drug conjugate for acute myeloid leukaemia
    Smith, Lan-Lan
    LANCET ONCOLOGY, 2017, 18 (01): : 26 - 26
  • [7] Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
    Voutsadakis, IA
    ANTI-CANCER DRUGS, 2002, 13 (07) : 685 - 692
  • [8] ACQUISITION OF CD13 AND CD33 EXPRESSION AT RELAPSE ON ACUTE MYELOID-LEUKEMIA CELLS WITH AN UNUSUAL PHENOTYPE - MPO+CD13-CD33-
    KAWADA, H
    ICHIKAWA, Y
    KOBAYASHI, N
    FUKUDA, R
    YONEKURA, S
    NAGAO, T
    INTERNAL MEDICINE, 1993, 32 (09) : 733 - 736
  • [9] Acute myeloid leukaemia stem cells express the CD33 antigen.
    Taussig, D
    Pearce, DJ
    Simpson, C
    Rohatiner, A
    Lister, TA
    Bonnet, D
    BLOOD, 2003, 102 (11) : 143B - 143B
  • [10] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
    Stasi, Roberto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 527 - 540
12345